vimarsana.com

Latest Breaking News On - Michaelj morris - Page 1 : vimarsana.com

JNJ-6420 Elicits Responses in mCRPC, But Safety Concerns Arise

A novel radioligand therapy, JNJ-6420, demonstrates potential in treating mCRPCr, delivering sustained responses following only 1-2 doses.

ASCO 2024: A Phase 1 Study of JNJ-69086420 (JNJ-6420), an Actinium-225 (225Ac)-Labeled Antibody Targeting Human Kallikrein 2, for mCRPC

ASCO 2024, prostate cancer, metastatic castration-resistant prostate cancer (mCRPC), JNJ-69086420 (JNJ-6420), Actinium-225 (225Ac), Targeting Human Kallikrein 2, JNJ-6420 adverse events.

Naheed Bardai, Rochelle Wempe, Michael Morris appointed to Saskatchewan courts

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.